Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03789318 · ClinicalTrials.gov registry record · Phase 2
Study in Subjects Undergoing Complete Abdominoplasty
A Phase 2 study of Postsurgical Pain, sponsored by Concentric Analgesics.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT03789318 is a Phase 2 study of Postsurgical Pain that has completed, run by Concentric Analgesics. The registered enrollment target is 54 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03789318, a Phase 2 study of Postsurgical Pain, has completed, sponsored by Concentric Analgesics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 2, single center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 vs. placebo in subjects undergoing an elective C-ABD under general anesthesia supplemented with a bupivacaine hydrochloride (HCl)transverse abdominis plane (TAP) block.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Hydromorphone
- DRUG Bupivacaine Hydrochloride
- DRUG Fentanyl
- DRUG CA-008 5 mg
Study Locations (1)
California
- Lotus Clinical Research, LLC - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2019-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03789318
The ClinicalTrials.gov registry entry for NCT03789318 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concentric Analgesics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postsurgical Pain appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT03789318 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03789318 about?
NCT03789318 is a clinical study titled "Study in Subjects Undergoing Complete Abdominoplasty". Phase 2, single center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 vs. placebo in subjects undergoing an elective C-ABD under general anesthesia supplemented with a bupivacaine hydrochloride (HCl)transverse abdominis plane (TAP) block.
What is the current status of trial NCT03789318?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2018-12-03. Estimated completion is 2019-06-12.
What conditions does trial NCT03789318 study?
This clinical trial studies the following conditions: Postsurgical Pain.
What interventions are being tested in trial NCT03789318?
The interventions under investigation include: Placebo (DRUG), Hydromorphone (DRUG), Bupivacaine Hydrochloride (DRUG), Fentanyl (DRUG), CA-008 5 mg (DRUG).
Who is sponsoring clinical trial NCT03789318?
This trial is sponsored by Concentric Analgesics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03789318 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postsurgical Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.